Skip to main content
Top
Published in: Respiratory Research 1/2024

Open Access 01-12-2024 | Idiopathic Pulmonary Fibrosis | Research

Potential role of SIRT-1 and SIRT-3 as biomarkers for the diagnosis and prognosis of idiopathic pulmonary fibrosis

Authors: Fabio Perrotta, Vito D’Agnano, Domenica Francesca Mariniello, Giuseppe Castaldo, Maria Vitale, Mario Cazzola, Andrea Bianco, Filippo Scialò

Published in: Respiratory Research | Issue 1/2024

Login to get access

Abstract

Background

Idiopathic pulmonary fibrosis (IPF) is a debilitating and progressive lung disease of unknown aetiology, characterized by the relentless deposition of fibrotic tissue. Biomarkers may play a pivotal role as indicators of disease presence, progression, and treatment response. Sirtuins, a family of enzymes with ADP ribosyltransferase or deacetylase activity, have been implicated in several diseases, including pulmonary fibrosis.

Methods

A cross-sectional, prospective, observational single-center study was conducted to investigate the potential role of serum SIRTs levels as biomarkers in patients with IPF. Demographic, clinical, and functional data and serological samples were collected from 34 patients with IPF followed at the Interstital Lung and Rare Diseases Outpatient Clinic of the Vanvitelli Pneumology Clinic, Monaldi Hospital, Naples, Italy and from 19 age-matched controls.

Results

Serum SIRT-1 levels were significantly reduced in IPF patients compared to controls (median IPF 667 [435–858] pg/mL versus controls 925 [794–1173] pg/mL; p < 0.001 ). In contrast, serum SIRT-3 levels were significantly increased in IPF patients compared to controls (median IPF 338 [230–500] pg/mL versus controls 154 [99.8–246] pg/mL; p < 0.001). There were no statistically significant differences in serum SIRT-6 and SIRT-7 levels between IPF and controls. In addition, we found a significant positive correlation between SIRT-1 and lung function parameters such as FEV1% (ϱ=0.417;p = 0.016), FVC% (ϱ=0.449;p = 0.009) and DLCO% (ϱ=0.393;p = 0.024), while a significant negative correlation was demonstrated between SIR-1 and GAP score, demonstrating a significant reduction in SIRT-1 in advanced Gender-Age-Physiology (GAP) stages 2–3 compared to GAP stage 1 (p = 0.008).

Conclusions

This prospective, cross-sectional study showed that SIRT-1 was associated with lung function and IPF severity and that both SIRT-1 and SIRT-3 could be considered as potential biomarkers of IPF, whereas SIRT-6 and SIRT-7 were not associated with IPF.
Literature
13.
16.
go back to reference Chandel A, King CS, Ignacio RV, Pastre J, Shlobin OA, Khangoora V, Aryal S, Nyquist A, Singhal A, Flaherty KR, et al. External validation and longitudinal application of the DO-GAP Index to Individualise Survival Prediction in Idiopathic Pulmonary Fibrosis. ERJ open Res. 2023;9. https://doi.org/10.1183/23120541.00124-2023. Chandel A, King CS, Ignacio RV, Pastre J, Shlobin OA, Khangoora V, Aryal S, Nyquist A, Singhal A, Flaherty KR, et al. External validation and longitudinal application of the DO-GAP Index to Individualise Survival Prediction in Idiopathic Pulmonary Fibrosis. ERJ open Res. 2023;9. https://​doi.​org/​10.​1183/​23120541.​00124-2023.
18.
go back to reference Manetti M, Rosa I, Fioretto BS, Matucci-Cerinic M, Romano E. Decreased serum levels of SIRT1 and SIRT3 correlate with severity of skin and lung fibrosis and peripheral microvasculopathy in systemic sclerosis. J Clin Med. 2022;11. https://doi.org/10.3390/jcm11051362. Manetti M, Rosa I, Fioretto BS, Matucci-Cerinic M, Romano E. Decreased serum levels of SIRT1 and SIRT3 correlate with severity of skin and lung fibrosis and peripheral microvasculopathy in systemic sclerosis. J Clin Med. 2022;11. https://​doi.​org/​10.​3390/​jcm11051362.
20.
go back to reference Rong L, Wu J, Wang W, Zhao R-P, Xu X-W, Hu D. Sirt 1 activator attenuates the Bleomycin-Induced Lung Fibrosis in mice via inhibiting epithelial-to-mesenchymal transition (EMT). Eur Rev Med Pharmacol Sci. 2016;20:2144–50.PubMed Rong L, Wu J, Wang W, Zhao R-P, Xu X-W, Hu D. Sirt 1 activator attenuates the Bleomycin-Induced Lung Fibrosis in mice via inhibiting epithelial-to-mesenchymal transition (EMT). Eur Rev Med Pharmacol Sci. 2016;20:2144–50.PubMed
21.
go back to reference Cheresh P, Kim S-J, Jablonski R, Watanabe S, Lu Z, Chi M, Helmin KA, Gius D, Budinger GRS, Kamp DW. SIRT3 overexpression ameliorates asbestos-Induced Pulmonary Fibrosis, Mt-DNA damage, and lung fibrogenic monocyte recruitment. Int J Mol Sci. 2021;22. https://doi.org/10.3390/ijms22136856. Cheresh P, Kim S-J, Jablonski R, Watanabe S, Lu Z, Chi M, Helmin KA, Gius D, Budinger GRS, Kamp DW. SIRT3 overexpression ameliorates asbestos-Induced Pulmonary Fibrosis, Mt-DNA damage, and lung fibrogenic monocyte recruitment. Int J Mol Sci. 2021;22. https://​doi.​org/​10.​3390/​ijms22136856.
25.
go back to reference Minagawa S, Araya J, Numata T, Nojiri S, Hara H, Yumino Y, Kawaishi M, Odaka M, Morikawa T, Nishimura SL, et al. Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-Induced Senescence of Human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2011;300:L391–401. https://doi.org/10.1152/ajplung.00097.2010.CrossRefPubMed Minagawa S, Araya J, Numata T, Nojiri S, Hara H, Yumino Y, Kawaishi M, Odaka M, Morikawa T, Nishimura SL, et al. Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-Induced Senescence of Human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2011;300:L391–401. https://​doi.​org/​10.​1152/​ajplung.​00097.​2010.CrossRefPubMed
Metadata
Title
Potential role of SIRT-1 and SIRT-3 as biomarkers for the diagnosis and prognosis of idiopathic pulmonary fibrosis
Authors
Fabio Perrotta
Vito D’Agnano
Domenica Francesca Mariniello
Giuseppe Castaldo
Maria Vitale
Mario Cazzola
Andrea Bianco
Filippo Scialò
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2024
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-024-02796-0

Other articles of this Issue 1/2024

Respiratory Research 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.